rituximab

November 13, 2018

Rituxan Shows Similar Benefit With or Without Chemo in Indolent Lymphomas, Study Finds

News

Using Rituxan (rituximab) as first-line treatment for indolent — or slow-growing — lymphomas leads to similar long-term survival as regimens containing both Rituxan and chemotherapy, a study shows. The approach also eliminated ... Read more

September 19, 2018September 19, 2018

Rituxan-Revlimid Combo Effective in Treating Advanced Follicular Lymphoma, Study Shows

News

Patients with previously untreated follicular lymphoma may soon be able to replace a regimen of chemotherapy and Rituxan (rituximab) with Rituxan and Revlimid (lenalidomide) after a Phase 3 trial showed similar effectiveness for ... Read more

August 10, 2018August 9, 2018

Hope Matters As I Celebrate My 10-Year ‘Diagnosiversary’

Columns, Things That Give Me Hope - a Column by Bob McEachern

Last January, I celebrated my 10-year “diagnosiversary.” I received a diagnosis of follicular lymphoma, a slow-growing, but incurable blood cancer on Jan. 15, 2008. My diagnosiversary is always a celebration. ... Read more

August 2, 2018

Venclexta Triple Combo in NHL Patients Produces Long-lasting Responses in Phase 1 Trial

News

A combination of Venclexta (venetoclax), bendamustine, and Rituxan (rituximab) is tolerable and produces long-lasting responses in patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL), according to a Phase 1 trial. The study, “Venetoclax, bendamustine, ... Read more

July 19, 2018

Study Examines Prescription Rates for Rituximab Biosimilars in European NHL Patients

News

European patients with non-Hodgkin’s lymphoma (NHL) are more likely to receive rituximab biosimilars if they are fitter, have indolent disease, or follicular lymphoma, according to a new study. The study, “Treatment approach for ... Read more

June 19, 2018

Trial of Betalutin-Rituxan Combo as Second-line Follicular Lymphoma Therapy Poised to Launch in Norway

News

A Phase 1b trial evaluating a combination of Betalutin (177Lu-satetraxetan-lilotomab) and Rituxan (rituximab) as a second-line therapy for follicular lymphoma will begin soon in Norway following Nordic Nanovector receiving all necessary approvals. The trial, called Archer-1, ... Read more

June 8, 2018

Imbruvica-Rituxan Combo Significantly Delays Progression of Rare Type of Lymphoma in Phase 3 Trial

News

A combination of Imbruvica (ibrutinib) and Rituxan (rituximab) significantly extends the time to disease worsening or death in patients with a rare type of lymphoma called Waldenström’s macroglobulinemia, a Phase 3 trial ... Read more

June 4, 2018

Alexo Begins Testing ALX148 Combinations in Phase 1 Trial of NHL, Solid Tumors

News

Alexo Therapeutics has started treating patients in the combination part of its Phase 1 trial, which will test multiple combinations of ALX148 with targeted antibody therapies — including Keytruda (pembrolizumab), Herceptin ... Read more

April 26, 2018April 26, 2018

Nearly Half of NHL Patients in Phase 1 Trial Respond to ALT-803, Rituxan Combo, Results Show

News

A combination of Rituxan (rituximab) and the experimental agent ALT-803 leads to a response rate of 48% in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma, according to preliminary data from a Phase ... Read more

February 23, 2018February 23, 2018

Imbruvica Only Moderately Effective in Relapsed Follicular Lymphoma Patients, Phase 2 Trial Shows

News

Imbruvica (ibrutinib) is only moderately effective against tumors in patients with relapsed follicular lymphoma, and certain clinical and genetic factors may have an impact on patient response, according to results ... Read more